ABD 400 mg Intas Pharmaceuticals

Description

ABD 400 mg Intas Pharmaceuticals: Overview and Features

The ABD 400 mg tablet from Intas Pharmaceuticals is primarily utilized in the management of specific cancer types, particularly prostate cancer. This pharmaceutical product falls under the category of Abiraterone acetate, which functions by inhibiting androgen biosynthesis. The medication is generally recommended for use in combination with prednisone, enhancing its efficacy for patients. Its carefully formulated components contribute towards regulating hormone levels, providing essential therapeutic benefits for those affected by androgen-dependent malignancies.

Product Components and Composition

The composition of ABD 400 mg includes a specific formulation designed to maximize its therapeutic impact while ensuring patient safety. Understanding the key components can enhance comprehension of its functioning.

• Active Substance: Abiraterone acetate
• Chemical Formula: C26H33NO2
• Structural Features: Includes a steroidal backbone with an acetate side group
• Strength: 400 mg
• Packing: Available in blister packs containing 10 tablets

These ingredients work in tandem to inhibit the production of androgens, which are involved in the progression of certain cancers.

ABD 400 mg Intas Pharmaceuticals: Safety Information

Safety is paramount when administering ABD 400 mg. It is essential to monitor patients for potential side effects or adverse reactions. Regular evaluations can mitigate risks associated with using the medication, given its profile.

• Hypertension: Increased blood pressure has been noted in some patients.
• Hypokalemia: A drop in serum potassium levels necessitates monitoring.
• Hepatotoxicity: Risks associated with liver function warrant attention.
• Edema: Swelling may occur, requiring assessment.
• Hot Flushes: Patients might experience sudden warmth.

It is advised that healthcare professionals conduct liver enzyme and serum potassium level tests regularly throughout treatment.

Therapeutic Mechanism and Benefits of the Treatment

ABD 400 mg provides significant therapeutic action through the inhibition of CYP17, an enzyme critical for testosterone synthesis. By reducing androgen production, the medication helps manage symptoms associated with prostate cancer, thereby contributing to improved patient outcomes. Its half-life of 12 hours allows for effective once-daily dosing, which simplifies the treatment regimen.

• Reduces androgen levels significantly
• Slows down cancer progression effectively
• In combination with prednisone, it enhances overall treatment efficacy
• Offers a convenient dosing schedule

Incorporating ABD 400 mg into cancer treatment plans can lead to improved quality of life for patients.

Recommended Dosage Instructions for Optimal Use

Administering the correct dosage is vital for the effectiveness of ABD 400 mg Intas Pharmaceuticals. The standard regimen recommended involves taking the tablets alongside prednisone to enhance therapeutic outcomes.

• Typical Dosage: 1,000 mg of ABD 400 mg once daily
• Prednisone: 5 mg twice daily as a complementary treatment
• Administration: Taken orally, with or without food
• Course of Treatment: As advised by healthcare professionals based on patient condition

Adhering to these guidelines can help ensure effective management of the patient’s health condition.

Conclusion on ABD 400 mg Intas Pharmaceuticals and Its Efficacy

In summary, ABD 400 mg Intas Pharmaceuticals serves as a crucial component in cancer therapy, specifically for conditions that benefit from androgen suppression. Its well-researched formula, combined with appropriate usage and monitoring, can significantly enhance treatment outcomes. With its competitive price of $7.00, accessible packaging, and reliable performance, ABD 400 mg remains a trusted choice for healthcare providers managing prostate cancer.